CEL-SCI Reports on NYSE American Noncompliance Notice and Compliance Plan

CEL-SCI Corporation (NYSE American: CVM) reported on a
communication received today from the staff of the NYSE American, its
current listing exchange, that it considered the Company to be
noncompliant with certain listing requirements based on its quarterly
report for the period ended March 31, 2018. The Company has been given
the opportunity to maintain its listing by submitting a plan of
compliance by August 13, 2018. This plan must advise of actions the
Company has taken or will take to regain compliance with the continued
listing standards by January 14, 2019. The Company intends to submit
such a plan by August 13, 2018.

Based on the Company’s quarterly report on Form 10-Q for the period
ended March 31, 2018, the Company is below compliance with Section
1003(a)(i), Section 1003(a)(ii) and Section 1003(a)(iii) of the listing
requirements of the Exchange since it reported a stockholders’ equity
deficit as of March 31, 2018 and had net losses in its 5 most recent
fiscal years ended September 30, 2017. Additional information and
provisions regarding the NYSE American requirements are found in Part 10
of its Company Guide.

Geert Kersten, CEO of CEL-SCI said: “Noncompliance with the rules cited
above came about a result of our total market capitalization having
fallen below $50 million. The Exchange will not normally consider
suspending dealings in, or removing from listing, the securities of an
issuer which is otherwise below the stockholders’ equity criteria in the
sections noted above but has a market capitalization of at least $50
million. Therefore one of the ways we can regain compliance is by
achieving and maintaining market capitalization of at least $50 million.
Since we have a major, almost completed Phase 3 cancer study where the
last patient was enrolled almost two years ago, we think that many
investors may become interested in our company this summer and fall in
anticipation of the conclusion of the study.”

The communication and compliance plan has no current effect on the
listing of the Company’s shares on the Exchange. If the plan is not
acceptable or the Company does not make sufficient progress under the
plan or reestablish compliance by January 14, 2019, then staff of the
Exchange may initiate proceedings for delisting from the NYSE American.
The Company may then appeal a staff determination to initiate such
proceedings in accordance with the Exchange’s Company Guide.

About CEL-SCI Corporation

CEL-SCI is a Phase 3 cancer immunotherapy company. The Phase 3 study is
fully enrolled with 928 patients. When it comes to cancer immunotherapy,
CEL-SCI believes it is most logical to boost the patient’s immune system
while it is still intact in order to have the greatest possible impact
on survival. Therefore, in CEL-SCI’s pivotal Phase 3 study patients who
are newly diagnosed with advanced head and neck cancer are treated first
with its lead investigational immunotherapy Multikine (Leukocyte
Interleukin, Injection)*, BEFORE they receive surgery, radiation and/or
chemotherapy. This approach is unique. Most other cancer immunotherapies
are used only after conventional therapies have been tried and/or
failed. Head and neck cancer represents about 6% of all cancers.
Multikine has received Orphan Drug designation from the FDA for the
treatment of head and neck cancer patients with advanced squamous cell
carcinoma. CEL-SCI has received patents for Multikine from the US,
Europe, China and Japan.

The Company’s LEAPS technology is currently being developed as a
therapeutic vaccine for rheumatoid arthritis and is supported by grants
from the National Institutes of Health. The Company has operations in
Vienna, Virginia, and in/near Baltimore, Maryland.

Forward-Looking Statements

This press release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange Act of 1934, as amended. When
used in this press release, the words “intends,” “believes,”
“anticipated,” “plans” and “expects,” and similar expressions, are
intended to identify forward-looking statements. Such statements are
subject to risks and uncertainties that could cause actual results to
differ materially from those projected. Factors that could cause or
contribute to such differences include, an inability to duplicate the
clinical results demonstrated in clinical studies, timely development of
any potential products that can be shown to be safe and effective,
receiving necessary regulatory approvals, difficulties in manufacturing
any of the Company’s potential products, inability to raise the
necessary capital and the risk factors set forth from time to time in
CEL-SCI’s filings with the Securities and Exchange Commission, including
but not limited to its report on Form 10-K for the year ended September
30, 2017. The Company undertakes no obligation to publicly release the
result of any revision to these forward-looking statements which may be
made to reflect the events or circumstances after the date hereof or to
reflect the occurrence of unanticipated events.

* Multikine (Leukocyte Interleukin, Injection) is the trademark that
CEL-SCI has registered for this investigational therapy, and this
proprietary name is subject to FDA review in connection with the
Company’s future anticipated regulatory submission for approval.
Multikine has not been licensed or approved for sale, barter or exchange
by the FDA or any other regulatory agency. Similarly, its safety or
efficacy has not been established for any use. Moreover, no definitive
conclusions can be drawn from the early-phase, clinical-trials data
involving the investigational therapy Multikine. Further research is
required, and early-phase clinical trial results must be confirmed in
the Phase 3 clinical trial of this investigational therapy that is in
progress.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180713005384/en/

Leave a Comment